Sundar S K, Stefanescu I, Menezes J
Laboratory of Immunovirology of the Pediatric Research Center, Faculty of Medicine, University of Montreal, Ste-Justine Hospital, Quebec, Canada.
Int J Immunopharmacol. 1987;9(8):869-73. doi: 10.1016/0192-0561(87)90002-6.
Patients with Epstein-Barr virus (EBV)-associated dissorders usually demonstrate evidence of immunosupression during active disease. Sera of some patients with EBV-induced infectious mononucleosis (IM), contain an IgG-blocking factor (IM-IgG) which inhibits in vitro cell-mediated immune responses and which we postulate plays an important role in viral immunosuppression. We had shown earlier that Isoprinosine (an immunostimulator) has a counterinhibitory effect on this IM-IgG activity. Here we describe evidence showing for the first time that the immunosuppressive activity of IM-IgG is aimed at inhibition of interleukin-2 (IL-2) synthesis and does not affect IL-2 receptors.
患有爱泼斯坦-巴尔病毒（EBV）相关疾病的患者在疾病活动期通常表现出免疫抑制的证据。一些患有EBV诱导的传染性单核细胞增多症（IM）的患者血清中含有一种IgG阻断因子（IM-IgG），它能抑制体外细胞介导的免疫反应，我们推测它在病毒免疫抑制中起重要作用。我们之前已经表明，异丙肌苷（一种免疫刺激剂）对这种IM-IgG活性有抗抑制作用。在此我们首次描述了证据，表明IM-IgG的免疫抑制活性旨在抑制白细胞介素-2（IL-2）的合成，而不影响IL-2受体。
